660 - In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Virtual

Presenting Author(s)

Anne Laurence Santerre Henriksen, PhD

Managing Partner
Maxel Consulting ApS
Jyllinge, Sjelland, Denmark

CL

Christopher M. Longshaw, PhD

Senior Director, Scientific Affairs EU
Shionogi B.V.
London, England, United Kingdom
Dee Shortridge, PhD

Senior Director Microbiology
JMI Laboratories
North Liberty, Iowa, United States
JS

Jennifer M. Streit, BS, MT(ASCP)

Surveillance Manager
JMI Laboratories
North Liberty, Iowa, United States
MT

Miki Takemura, n/a

Director, Head of Infectious Diseases 5, Laboratory for Drug Discovery and Disease Research
Shionogi & Co., Ltd
Toyonaka, Osaka, Japan
YY

Yoshinori Yamano, PhD (he/him/his)

Chief Scientific Officer for Infectious Diseases
Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan